Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers
Yueming Zhu, … , Bin Zhang, Yong Wan
Yueming Zhu, … , Bin Zhang, Yong Wan
Published March 26, 2024
Citation Information: J Clin Invest. 2024;134(10):e176390. https://doi.org/10.1172/JCI176390.
View: Text | PDF
Research Article Oncology

Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers

  • Text
  • PDF
Abstract

Despite widespread utilization of immunotherapy, treating immune-cold tumors remains a challenge. Multiomic analyses and experimental validation identified the OTUD4/CD73 proteolytic axis as a promising target in treating immune-suppressive triple negative breast cancer (TNBC). Mechanistically, deubiquitylation of CD73 by OTUD4 counteracted its ubiquitylation by TRIM21, resulting in CD73 stabilization inhibiting tumor immune responses. We further demonstrated the importance of TGF-β signaling for orchestrating the OTUD4/CD73 proteolytic axis within tumor cells. Spatial transcriptomics profiling discovered spatially resolved features of interacting malignant and immune cells pertaining to expression levels of OTUD4 and CD73. In addition, ST80, a newly developed inhibitor, specifically disrupted proteolytic interaction between CD73 and OTUD4, leading to reinvigoration of cytotoxic CD8+ T cell activities. In preclinical models of TNBC, ST80 treatment sensitized refractory tumors to anti-PD-L1 therapy. Collectively, our findings uncover what we believe to be a novel strategy for targeting the immunosuppressive OTUD4/CD73 proteolytic axis in treating immune-suppressive breast cancers with the inhibitor ST80.

Authors

Yueming Zhu, Anupam Banerjee, Ping Xie, Andrey A. Ivanov, Amad Uddin, Qiao Jiao, Junlong Jack Chi, Lidan Zeng, Ji Young Lee, Yifan Xue, Xinghua Lu, Massimo Cristofanilli, William J. Gradishar, Curtis J. Henry, Theresa W. Gillespie, Manali Ajay Bhave, Kevin Kalinsky, Haian Fu, Ivet Bahar, Bin Zhang, Yong Wan

×

Figure 3

Mapping of molecular regions that facilitate the interaction between CD73 and OTUD4 and 3D structural modeling of CD73 regulation based on the interplay of ubiquitylation and deubiquitylation.

Options: View larger image (or click on image) Download as PowerPoint
Mapping of molecular regions that facilitate the interaction between CD7...
(A–D) Schematic diagram of human OTUD4 domains and strategy to engineer a series of OTUD4 deletion mutants. Mapping of the molecular domain on OTUD4 involving in the interaction with CD73. The interactions between CD73 and OTUD4 fragments were examined by coimmunoprecipitation experiments in HEK-293T cells. Amino acids stretching from 380–410 on OTUD4 (D) were identified as the region that mediates the interaction between OTUD4 and CD73. (E) Schematic diagram of human CD73 domains and strategy to engineer a series of CD73 deletion fragments. (F) The interactions between OTUD4 and CD73 fragments were determined. Amino acids stretching from 275–311 on CD73 were identified as the region that mediates the interaction between OTUD4 and CD73. (G) Structural model for the interaction of CD73 with OTUD4. Residues R380–N410 (red) of OTUD4 (green) interact with the residues V275–D311 (yellow) of CD73 (cyan). Salt bridges are formed between E296 and E293 of CD73 and K409 and K403 of OTUD4, respectively. The interface is further stabilized by hydrophobic interactions between V300 and V301 of CD73 (yellow) and F404 (red) of OTUD4, and contacts between H304 (yellow) of CD73 and S397 (red) of OTUD4. (H) Validation of interaction domains between OTUD4 with CD73 by coimmunoprecipitation of ectopic V5-tagged CD73WT and V5-tagged CD73V300P/I301Q mutant in HEK-293T cells. The ubiquitylation status of CD73WT and CD73V300P/I301Q mutant was also determined. (I) MDA-MB468-CD73WT and MDA-MB468-CD73V300P/I301Q cells were treated with CHX and MG-132 and CD73 protein turnover were determined. (J) The adenosine levels were determined in MDA-MB468-CD73WT and MDA-MB468-CD73V300P/I301Q. (K) MDA-MB468, MDA-MB468-CD73WT and MDA-MB468-CD73V300P/I301Q were cocultured with human PBMCs and percentage of IFN-γ + in CD8+ T cell population quantified using flow cytometry. Data (mean ± SEM) are representative of at least 3 independent experiments. **P < 0.01 and ***P < 0.001, by unpaired t test, 1-way ANOVA with Tukey’s multiple comparisons test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts